Updated August 2026. Establishing a blood bank or plasma collection centre in the UAE involves one of the most tightly regulated healthcare licensing pathways in the country, governed by the Ministry of Health and Prevention (MOHAP), the Dubai Health Authority (DHA), the Department of Health Abu Dhabi (DOH), and the UAE National Blood Transfusion and Research Centre (NBTS). The UAE’s blood services sector operates on a voluntary non-remunerated donor model consistent with World Health Organisation (WHO) global blood safety standards. Any commercial, hospital-based, or standalone blood bank or plasma fractionation operation must comply with stringent facility, safety, GMP, and donor ethics requirements before opening to the public or initiating blood product activities.
- MOHAP Blood Bank Regulations prohibit paid blood donation; only voluntary, non-remunerated donation is legally permitted in the UAE.
- DHA blood storage facility licence costs AED 20,000–60,000, with annual renewal fees and additional product registration requirements.
- Full blood bank setup investment—covering cold storage, processing equipment, testing laboratory, and GMP infrastructure—ranges from AED 50,000 to AED 200,000 in regulatory and fitout costs.
- Blood product import into the UAE requires a MOHAP import permit per product batch; each imported product must be MOHAP-registered before use in patients.
- Fractionation plant operations require an additional MOHAP industrial pharmaceutical manufacturing permit beyond the standard blood bank licence.
Overview of the UAE Blood Services Sector
The UAE National Blood Transfusion and Research Centre (NBTS), operating under MOHAP, serves as the apex body coordinating voluntary blood donation campaigns, quality standards for blood banks, and national blood safety programmes across all seven emirates. The UAE aims for full self-sufficiency in blood supply under its National Blood Programme, reducing reliance on imported blood products. Hospital-based blood banks are the most common facility type, operating in major public and private hospitals to serve surgical, oncology, and trauma patient needs.
Standalone plasma collection centres and fractionation facilities are emerging as a distinct segment, driven by global demand for plasma-derived medicinal products (PDMPs) such as immunoglobulins, albumin, and clotting factors. However, the UAE’s voluntary-only donor model places constraints on the volume of source plasma that can be collected domestically compared to countries that permit paid plasma donation. Understanding these policy constraints is essential for any investor evaluating UAE-based plasma operations.
MOHAP Blood Bank Regulations and Voluntary Donor Policy
MOHAP Blood Bank Regulations (Federal Ministerial Decision No. 260 of 2016 and subsequent updates) establish the foundational legal framework for all blood banking operations in the UAE. The regulations mandate that all blood and blood component collection must be on a voluntary, non-remunerated basis. Cash payments, gifts of significant value, paid leave, or any other material incentives offered in exchange for blood donation are strictly prohibited. This aligns the UAE with WHO Resolution WHA63.12 on voluntary non-remunerated blood donation.
Blood banks must establish formal donor selection protocols compliant with MOHAP standards, including medical history questionnaires, haemoglobin screening, infectious disease testing (HIV, HBV, HCV, syphilis, malaria in endemic-risk donors), and ABO/Rh blood group typing. Donor deferral criteria are specified in MOHAP Technical Standards for Blood Banks and must be consistently applied. All donors must provide written informed consent before phlebotomy. Blood banks must maintain a donor registry and adverse event reporting system accessible to MOHAP inspectors.
DHA Blood Storage Facility Licence
A hospital or standalone facility in Dubai wishing to store, process, or issue blood products—including whole blood, packed red blood cells, fresh frozen plasma (FFP), platelets, and cryoprecipitate—must obtain a Blood Storage Facility licence from the DHA. The DHA licence application requires facility floor plans showing dedicated blood storage areas with validated cold storage equipment (4°C refrigerators, -18°C or -30°C freezers, platelet agitators), a transfusion laboratory, and a separate quarantine storage area for untested or non-conforming products.
Initial DHA blood storage facility licence fees range from AED 20,000 to AED 60,000 depending on the scope of operations (storage only vs. processing and component preparation). Annual renewal fees are AED 12,000–30,000. Facilities that both collect and process blood—whole blood collection, component separation, testing, and labelling—require a higher-tier facility licence and a designated transfusion medicine specialist on staff. Cold chain validation documentation, temperature excursion management procedures, and blood product recall protocols are mandatory components of the DHA licence application.
Blood Product Import and MOHAP Registration
The UAE imports a substantial volume of blood products and plasma-derived medicinal products (PDMPs) from international manufacturers, primarily from Europe, the United States, and Australia. Every imported blood product—packed red blood cells, platelets, FFP, albumin, intravenous immunoglobulin (IVIG), coagulation factors, and Rh immunoglobulin—must be individually registered with MOHAP’s Drug Control Department before it may be imported or administered to patients in UAE facilities.
MOHAP product registration for blood products requires submission of product dossiers including European Pharmacopoeia or USP monograph compliance, manufacturing facility GMP certificates (EMA, FDA, or TGA inspection reports), product stability data, and quality certificates for each batch proposed for import. Import permits are issued per shipment batch and require MOHAP registration numbers to be declared on customs documentation. Cold chain maintenance certificates must accompany each imported blood product shipment, and temperature breach incidents during shipping must be reported to MOHAP within 24 hours of discovery.
GMP Standards for Blood Products and Fractionation
Blood product processing—component preparation, pathogen reduction treatment, and labelling—must comply with Good Manufacturing Practice (GMP) standards as specified in the WHO Guidelines for Good Manufacturing Practices for Blood Establishments (WHO Technical Report Series No. 999, Annex 4). UAE-licensed blood banks implementing pathogen reduction technology (PRT) for plasma, platelets, or red blood cells must validate the PRT system in accordance with CE-marked or FDA-cleared device specifications and notify DHA of the implementation.
Fractionation operations—converting pooled source plasma into PDMPs—require a separate MOHAP Industrial Pharmaceutical Manufacturing Permit in addition to the blood bank licence. This permit applies GMP requirements equivalent to those governing pharmaceutical manufacturing facilities, including validation of all critical manufacturing processes, qualified person (QP) oversight, batch release documentation, environmental monitoring, and MOHAP pre-approval for any manufacturing process change. As of 2026, no large-scale fractionation plant operates commercially within the UAE, making this an emerging opportunity subject to MOHAP’s evolving regulatory guidance.
National Blood Programme and NBTS Coordination
The UAE National Blood Transfusion and Research Centre (NBTS) operates under MOHAP and serves as the national coordinator for the UAE National Blood Programme, which aims to build a self-sufficient, safe, and sustainable national blood supply. NBTS coordinates national blood donation campaigns including the annual UAE National Blood Donation Month and coordinates inter-hospital blood transfer protocols during shortage events. All licensed blood banks—public and private—are expected to participate in NBTS reporting, submitting quarterly blood product utilisation and inventory data to the national database.
NBTS also operates the National Haemovigilance Programme, which requires blood banks to report transfusion-related adverse events, near-misses, and product errors to a central registry. This data is used to generate national blood safety reports published biennially by MOHAP. Participation in haemovigilance reporting is a licence renewal condition for all licensed UAE blood banks as of the 2024 DHA and MOHAP regulatory update cycle.
Setting Up a Blood Bank: Facility and Equipment Requirements
A fully operational hospital blood bank or standalone blood storage facility in the UAE requires: validated blood storage refrigerators (4°C ± 2°C, with continuous temperature monitoring and alarm systems), platelet incubator-agitators (22°C ± 2°C), validated plasma freezers (-18°C or -30°C), a cross-matching and compatibility testing laboratory, a cryopreservation setup for rare blood types if applicable, a clean room or class B laminar flow area for component processing, and a dedicated quarantine area for unlabelled or untested products.
Total setup investment for a mid-scale hospital blood bank in the UAE—covering cold storage equipment, laboratory analysers (blood grouping, infectious disease testing), IT blood management system, and fitout—typically ranges from AED 500,000 to AED 1.5 million in capital equipment costs, with AED 50,000–200,000 in regulatory fees and facility compliance costs. Standalone plasma collection centres have a somewhat lower capital equipment burden but still require validated phlebotomy stations, plasma separation equipment, cold storage, and qualified phlebotomy and laboratory staff.
| Regulatory Item | Authority | Fee / Cost (AED) | Cycle |
|---|---|---|---|
| Blood Storage Facility Licence (Dubai) | DHA | 20,000–60,000 | Annual |
| Blood Bank Licence (Northern Emirates) | MOHAP | 15,000–40,000 | Annual |
| Blood Product Import Permit (per batch) | MOHAP | 1,000–5,000 | Per shipment |
| MOHAP Blood Product Registration | MOHAP | 5,000–15,000 per product | 5 years |
| Industrial Pharma Permit (Fractionation) | MOHAP | 50,000–150,000 | Annual |
| Blood Facility Licence (Abu Dhabi) | DOH | 25,000–70,000 | Annual |
Frequently Asked Questions
Is paid blood donation legal in the UAE?
No. MOHAP Blood Bank Regulations strictly prohibit remunerated blood donation. All blood collected in UAE-licensed facilities must be from voluntary, non-remunerated donors. Offering cash, significant gifts, or material incentives in exchange for blood donation is a regulatory violation that can result in immediate facility closure and prosecution. This policy aligns with WHO global blood safety standards.
What is the NBTS and what role does it play for private blood banks?
The UAE National Blood Transfusion and Research Centre (NBTS), operating under MOHAP, coordinates the National Blood Programme, runs national donation campaigns, and operates the National Haemovigilance Programme. All licensed blood banks—public and private—must submit quarterly blood product utilisation data to NBTS and report transfusion-related adverse events to the national haemovigilance registry. NBTS participation is a mandatory licence renewal condition under the 2024 DHA and MOHAP regulatory cycle.
Can imported blood products be used in UAE hospitals without MOHAP registration?
No. Every blood product and plasma-derived medicinal product imported into the UAE must be individually registered with MOHAP’s Drug Control Department. Import permits are batch-specific and must reference MOHAP registration numbers on customs documents. Cold chain certificates are required with each shipment. Unregistered blood products may not be administered to patients in any UAE-licensed healthcare facility.
What does a blood bank setup cost in the UAE?
Regulatory and fitout costs for a mid-scale UAE blood bank range from AED 50,000 to AED 200,000. Capital equipment—blood storage refrigerators, platelet agitators, plasma freezers, blood grouping analysers, and IT blood management systems—adds AED 500,000 to AED 1.5 million for a full hospital blood bank. DHA or MOHAP licence fees are AED 15,000–60,000 depending on emirate and scope of operations.
Is plasma fractionation permitted in the UAE?
Plasma fractionation into plasma-derived medicinal products requires a MOHAP Industrial Pharmaceutical Manufacturing Permit in addition to the blood bank licence, applying full pharmaceutical GMP standards. No large-scale commercial fractionation plant currently operates within the UAE. Investors exploring fractionation opportunities must engage with MOHAP’s pharmaceutical manufacturing division early in the planning phase for regulatory pathway guidance, as the framework is still evolving.